NASDAQ · DTIL
Healthcare · Biotechnology
$8.72
Up+$0.13 (+1.49%)
Updated Aug 21, 2026, 11:21 PM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
DTIL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning DTIL.
DTIL research
Company profile and research snapshot.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 9, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | Oppenheimer | Outperform | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.
SeekingAlpha · Aug 18, 2026
Precision BioSciences' direct clinical evidence and pipeline optionality outweigh the early-stage risks. Find out why DTIL stock is a speculative Buy.
ChartMill · Aug 8, 2026
Precision BioSciences (DTIL) passes Minervini Trend Template and high-growth momentum screen with uptrend, strong RS, and accelerating fundamentals.
Benzinga · Aug 3, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DTIL.
